GSK Glaxosmithkline plc - ADR

$GSK 👀 Really like the structure developing on the 6M chart. GSK recently broke above a multi-year descending trendline and now appears to be coming back for a potential bullish pennant breakout retest around the $50 area. If this former resistance continues to hold as support, I’ll be watching for the next higher-low and continuation move. This is a long-term swing setup, so patience is key. 📈

$GSK What is going on here? Sold all minutes into open this morning. Ideas? Unexpected. GSK had been decent stock.

The research continues and the AI overlords have been assigned another FDA decision to predict. Let's see how close it can get to it's predictions. $GSK — PDUFA: Oct. 26 Bepirovirsen for chronic hepatitis B. Priority Review + Breakthrough Therapy, backed by Phase 3 B-Well 1 & 2 where functional cure hit 19% vs. 0% with SoC alone. AI model call: • Approval probability: 95% • Estimated move on approval: +1.3% • Estimated move on miss: -1.7%

$GSK Excellent entry point. Strong support at 48.98. Worth $65 and they do have some mRNA expertise. Don't expect Moderna like action but up and to the right. Nice steady gainer for the future.

$GSK Good place to have some of your portfolio. Green. New leadership, good pipeline and dividend. Easy buy and hold.

A growing body of research suggests GSK’s Shingrix shingles vaccine may provide health benefits beyond preventing shingles, potentially including lower risks of cardiovascular disease and delayed dementia. However, doctors say more rigorous clinical evidence is needed before these potential benefits can be confirmed. A study published last month in Nature Medicine found that Shingrix was associated with a 10% lower risk of ischemic heart disease and a 12% lower risk of heart failure over seven years among Americans aged 60 and older, compared with people who received an older shingles vaccine that is no longer available in the U.S. Researchers are also examining whether protection against shingles and related viral activity could help delay or reduce the risk of dementia. The findings add to a growing area of research into possible links between vaccination, inflammation, viral infections and long-term health outcomes. $GSK